Latisse (Allergan) contains 0.03% bimatoprost, a synthetic prostamide compound which is also the active ingredient in Lumigan--a common glaucoma drug.   Allergan received FDA-approval for Latisse to market the medication as a treatment for eyelash hypotrichosis (thin, short, sparse, weak or inadequate eyelashes).   Applied nightly to the lid margin (where the lashes exit the skin), the medication increases the length, density, thickness and pigmentation of the existing lashes within weeks. 

At Bauman Medical Group, we've been using non-invasive treatments and eyelash transplants to help women (and even some men) regain, regrow, replace and/or enhance their eyelashes.  For more information, visit www.eyelash-transplant.com

updated link: FDA apporoves Latisse for Eyelash Growth